Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Operating Leases (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Operating Leases for 5 consecutive years, with $8.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases fell 17.28% to $8.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.1 million, a 17.28% decrease, with the full-year FY2024 number at $9.4 million, down 14.16% from a year prior.
  • Operating Leases was $8.1 million for Q3 2025 at Werewolf Therapeutics, down from $8.6 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $15.5 million in Q2 2022 to a low of $1.3 million in Q3 2021.
  • A 5-year average of $9.8 million and a median of $10.6 million in 2024 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: soared 941.96% in 2022, then decreased 24.71% in 2023.
  • Werewolf Therapeutics' Operating Leases stood at $14.6 million in 2021, then decreased by 13.63% to $12.6 million in 2022, then decreased by 12.76% to $11.0 million in 2023, then dropped by 14.16% to $9.4 million in 2024, then dropped by 13.73% to $8.1 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Operating Leases are $8.1 million (Q3 2025), $8.6 million (Q2 2025), and $9.0 million (Q1 2025).